scholarly journals A REVIEW ARTICLE ON SHATAPONAKA BHAGANDARA

2021 ◽  
Vol p5 (03) ◽  
pp. 2811-2816
Author(s):  
Radhika Pachamalai ◽  
Narmada M.G
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Diabetic Patient ◽  
Granulation Tissue ◽  
Review Article ◽  
Main Role ◽  
Sitz Bath ◽  
Fistula In Ano

Bhagandara disease has been explained in detail by Sushruta highlighting it as one among the Ashtama- hagada and out of five types of Bhagandara, Sambukavarta considered as Asadhya, remaining four are Kruchrasadhya. Bhagandara is a track lined by unhealthy granulation tissue, pus discharge and can be corre- lated with Fistula-in-Ano. Shataponaka (Vataja) Bhagandara which is having Nidana, Samprapthi, Pur- varupa, Rupa. Acharya Sushruta explained Shastra Karma with 4 unique incisions to avoid complication. The same procedure can be correlated to fistulotomy and fistulectomy which is told in Fistula-in-ano. Even though Ksharasutra popularly used in Bhagandara, Shastrakarma plays main role in Shataponaka Bhagandara. Conditions are like fistula-in-ano with multiple opening, Tubercular fistula-in-ano, Hidradenitis suppuritiva, Crohn’s disease with fistula-in-ano, Uncontrolled diabetic patient with multiple fistula-in-ano, Perianal acti- nomycosis can be included under Shataponaka Bhagandara. In order to avoid multiple incisions and to en- hance quick healing these incisions can be used in multiple track. Keywords: Shataponaka bhagandara, Tuberculosis fistula-in-ano, Hidradenitis suppuritiva, Sitz bath, Incisions.

scholarly journals Therapeutic role of methotrexate in pediatric Crohn’s disease

2018 ◽  
Vol 18 (3) ◽  
pp. 211-216
Author(s):  
Zlatko Djurić ◽  
Ljiljana Šaranac ◽  
Ivana Budić ◽  
Voja Pavlović ◽  
Jelena Djordjević
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Clinical Remission ◽  
Normal Growth ◽  
Mucosal Healing ◽  
Main Role ◽  
Therapeutic Role ◽  
Hepatosplenic T Cell Lymphoma ◽  
Maintenance Of Remission

The main role of therapy in Crohn’s disease (CD) is to achieve long-term clinical remission, and to allow for normal growth and development of children. The immunomodulatory drugs used for the maintenance of remission in CD include thiopurines (azathioprine and 6-mercaptopurine) and methotrexate (MTX). Development of hepatosplenic T-cell lymphoma in some patients with inflammatory bowel disease, treated with thiopurines only or in combination with anti-tumor necrosis factor agents, resulted in a growing interest in the therapeutic application of MTX in children suffering from CD. This review summarizes the literature on the therapeutic role of MTX in children with CD. MTX is often administered as a second-line immunomodulator, and 1-year clinical remission was reported in 25–69% of children with CD after excluding for the use of thiopurines. Initial data on MTX effectiveness in mucosal healing, and as a first-line immunomodulator in pediatric patients with CD, are promising. A definite conclusion, however, may only be made on the basis of additional research with a larger number of subjects.

Review article: distinctions between ileal and colonic Crohn's disease: from physiology to pathology

2021 ◽  
Author(s):  
Nicolas Pierre ◽  
Catherine Salée ◽  
Sophie Vieujean ◽  
Emeline Bequet ◽  
Angela‐Maria Merli ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Review Article
Sign in / Sign up

Export Citation Format

Share Document